Skip to main content
66°
Partly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bluebird Bio
(NQ:
BLUE
)
1.000
+0.100 (+11.11%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bluebird Bio
< Previous
1
2
3
4
5
6
7
Next >
bluebird bio stock is ripe for a 400% institutional short squeeze
February 27, 2024
Bluebird Bio stock could be on the verge of a 400% pop on earnings, management has set the writing on the wall for institutional buying to trickle in
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Is CRISPR Therapeutics the NVIDIA of gene editing?
February 26, 2024
CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
Gene therapy: Why does it cost millions for a single treatment?
February 15, 2024
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology.
Via
MarketBeat
Exposures
Product Safety
bluebird bio Inc. (NASDAQ: BLUE) Leading the Way in Wednesday Trading Based on Percentage Gain
July 19, 2023
Via
Investor Brand Network
bluebird bio Inc. (NASDAQ: BLUE) Leading the Way in Thursday Trading Based on Percentage Gain
April 13, 2023
Via
Investor Brand Network
2 low-priced gene therapy stocks to speculate on
January 08, 2024
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe
Via
MarketBeat
Exposures
Product Safety
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook
January 08, 2024
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
December 19, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
December 18, 2023
From
bluebird bio, Inc.
Via
Business Wire
Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
December 10, 2023
From
bluebird bio, Inc.
Via
Business Wire
Long-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events
December 09, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
December 08, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
December 08, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
November 07, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
November 02, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million
October 30, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio to Host Third Quarter 2023 Financial Results Conference Call
October 24, 2023
From
bluebird bio, Inc.
Via
Business Wire
Are Gene Therapy Stocks The Market's Next Big Winners?
September 25, 2023
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
bluebird bio Announces September Investor Events
September 05, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease
August 16, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress
August 08, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio to Host Second Quarter 2023 Financial Results Conference Call and Provide Commercial Update
July 25, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces FDA Priority Review of the Biologics License Application for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
June 21, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress
May 09, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events
April 27, 2023
From
bluebird bio
Via
Business Wire
bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
April 24, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress
March 29, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock
January 18, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
January 18, 2023
From
bluebird bio, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.